# Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection

> **NCT02562742** · — · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 554 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** REB

## Key facts

- **NCT ID:** NCT02562742
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-12
- **Primary completion:** 2017-06-12
- **Final completion:** 2017-06-12
- **Target enrollment:** 554 (ACTUAL)
- **Last updated:** 2017-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562742, "Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02562742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*